Cancer subtype identifier and method for classifying tumors
A cancer subtype identifier using PSI values from exon usage events and RNA expression classifies tumors into MXE1 and MXE2 subtypes, addressing the limitations of existing methods by providing accurate prognosis and enabling personalized treatment strategies.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- INDIVUMED GMBH
- Filing Date
- 2025-12-17
- Publication Date
- 2026-06-25
AI Technical Summary
Existing methods for classifying cancer subtypes and predicting prognosis are inadequate, particularly for colorectal cancer, due to limitations in molecular subtyping methods that lack precision and dynamic range, and do not account for patient variability within the same stage, leading to potential over-treatment and ineffective treatment regimens.
A cancer subtype identifier utilizing percent spliced-in (PSI) values derived from mutually exclusive exon usage events, expression of small nuclear RNAs, and protein-coding genes to classify tumors into MXE1 and MXE2 subtypes, which are associated with distinct prognoses, enabling more accurate patient stratification and treatment selection.
The method provides a reliable and cost-effective way to classify tumors into MXE1 and MXE2 subtypes, independent of conventional models, refining patient prognosis and enabling tailored treatment options based on the underlying biology of splicing and expression patterns, improving treatment efficacy and reducing over-treatment.
Smart Images
Figure IMGF000002_0001 
Figure IMGF000003_0001 
Figure IMGF000004_0001